PT2273994E - Formas de estado sólido de um produto farmacêutico - Google Patents

Formas de estado sólido de um produto farmacêutico Download PDF

Info

Publication number
PT2273994E
PT2273994E PT97267488T PT09726748T PT2273994E PT 2273994 E PT2273994 E PT 2273994E PT 97267488 T PT97267488 T PT 97267488T PT 09726748 T PT09726748 T PT 09726748T PT 2273994 E PT2273994 E PT 2273994E
Authority
PT
Portugal
Prior art keywords
pharmaceutical
solid state
state forms
forms
solid
Prior art date
Application number
PT97267488T
Other languages
English (en)
Portuguese (pt)
Inventor
K White Steven
Ivanisevic Igor
Stephens Kyle
Andres Mark
Wolf Brenton
Original Assignee
Neurmedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurmedix Inc filed Critical Neurmedix Inc
Publication of PT2273994E publication Critical patent/PT2273994E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
PT97267488T 2008-04-03 2009-04-03 Formas de estado sólido de um produto farmacêutico PT2273994E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4224008P 2008-04-03 2008-04-03

Publications (1)

Publication Number Publication Date
PT2273994E true PT2273994E (pt) 2016-03-15

Family

ID=41136126

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97267488T PT2273994E (pt) 2008-04-03 2009-04-03 Formas de estado sólido de um produto farmacêutico

Country Status (13)

Country Link
US (9) US8252947B2 (enExample)
EP (1) EP2273994B1 (enExample)
JP (2) JP2011527986A (enExample)
KR (1) KR101545300B1 (enExample)
CN (1) CN102215845A (enExample)
AU (1) AU2009231589B2 (enExample)
CA (1) CA2728889C (enExample)
DK (1) DK2273994T3 (enExample)
ES (1) ES2562069T3 (enExample)
HU (1) HUE028337T2 (enExample)
PL (1) PL2273994T3 (enExample)
PT (1) PT2273994E (enExample)
WO (1) WO2009124300A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028337T2 (en) * 2008-04-03 2016-12-28 Neurmedix Inc Shapes of a drug in a solid state
EP2300489B1 (en) 2008-06-06 2015-11-11 Harbor Therapeutics, Inc. Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
US20120220560A1 (en) * 2010-12-17 2012-08-30 White Steven K Steroid tetrol solid state forms
CN103768071B (zh) * 2012-10-23 2016-08-17 中国医药工业研究总院 一种治疗糖尿病的口服制剂
WO2019041078A1 (en) 2017-08-28 2019-03-07 Zhejiang Jiachi Pharmaceutical Development Ltd. ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES
EP4341271A4 (en) * 2021-05-18 2025-04-30 BioVie Inc. Compositions for treatment of neurodegenerative conditions
WO2024054452A1 (en) * 2022-09-06 2024-03-14 Biovie Inc. Methods for the treatment of mild cognitive impairment
CN120484042A (zh) * 2025-05-16 2025-08-15 中国人民解放军军事科学院军事医学研究院 一种he3286的合成方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329366A (en) * 1979-11-08 1982-05-11 Johnson & Johnson Products, Inc. Topical acylaminophenols
US4898694A (en) * 1987-11-25 1990-02-06 Schwartz Arthur G 17-Hydroxy-steroids
DE3801229A1 (de) 1988-01-18 1989-07-27 Krupp Polysius Ag Mahlverfahren sowie mahlanlage
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5641766A (en) * 1990-08-29 1997-06-24 Humanetics Corporation UP-regulation of immune system with Δ 5-Androstenes
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
ES2184729T3 (es) * 1990-08-29 2003-04-16 Humanetics Corp Proceso de tratamiento para promover la perdida de peso empleandio un 5-androsteno.
US5271944A (en) 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
US5922701A (en) * 1992-05-01 1999-07-13 University Of Utah Research Foundation Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue
US5424077A (en) 1993-07-13 1995-06-13 Church & Dwight Co., Inc. Co-micronized bicarbonate salt compositions
TW369521B (en) 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5455049A (en) 1995-01-04 1995-10-03 Ascent Pharmaceuticals, Inc. Terfenadine oral powder
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
US6686486B1 (en) * 1997-05-07 2004-02-03 Padma Marwah Process for effecting allylic oxidation
US5869709A (en) * 1997-05-07 1999-02-09 Humanetics Corporation Process for effecting allylic oxidation
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
WO1999047485A1 (en) * 1998-03-18 1999-09-23 Humanetics Corporation Process for effecting allylic oxidation using dicarboxylic acid imides and chromium reagents
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US20080015174A1 (en) * 1998-11-24 2008-01-17 Reading Christopher L Metabolic Disease Treatments
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US20060079492A1 (en) * 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
WO2001023405A2 (en) * 1999-09-30 2001-04-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
WO2001030802A2 (en) 1999-10-25 2001-05-03 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
US6274746B1 (en) * 2000-08-30 2001-08-14 Padma Marwah Process for allylic oxidation using metal hypochlorite and alkyl hydroperoxide
MXPA03005339A (es) * 2000-12-14 2004-03-26 Johnson & Johnson Productos de hormona esteroide que comprenden un agente de estabilizacion en forma no cristalina.
FR2820745A1 (fr) * 2001-02-14 2002-08-16 Oreal Procedes de preparation de la 7alpha-hydroxy- dehydroepiandrosterone
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
US7372941B2 (en) 2002-08-06 2008-05-13 Ssci, Inc. System and method for matching diffraction patterns
EP1678484A2 (en) 2003-10-27 2006-07-12 SSCI, Inc. Method for monte carlo indexing of powder diffraction data
US20070243620A1 (en) 2004-02-24 2007-10-18 Simon Bates Analysis and Screening of Solid Forms Using the Atomic Pair Distribution Function
AU2005330504B2 (en) * 2004-09-29 2010-10-28 Harbor Biosciences, Inc. Steroid analogs and characterization and treatment methods
US20060073099A1 (en) * 2004-10-01 2006-04-06 Frincke James M Treatment screening methods
US20060211604A1 (en) * 2004-11-26 2006-09-21 The Brigham And Women's Hospital, Inc. Methods for treating inflammatory disorders using regulators of microvessel dilations
US7964604B2 (en) * 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
CN103211821A (zh) 2006-04-22 2013-07-24 霍利斯—伊登医药公司 药物和用途
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
US8354396B2 (en) * 2006-11-17 2013-01-15 Harbor Therapeutics, Inc. Drug identification and treatment method
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
US20080153792A1 (en) * 2006-11-17 2008-06-26 Frincke James M Drug Identification and Treatment Method
DE102007063671A1 (de) * 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
JP2011511011A (ja) * 2008-02-05 2011-04-07 ハーバー バイオサイエンシーズ，インコーポレイテッド 医薬的固体状態形態
HUE028337T2 (en) 2008-04-03 2016-12-28 Neurmedix Inc Shapes of a drug in a solid state
EP2300489B1 (en) * 2008-06-06 2015-11-11 Harbor Therapeutics, Inc. Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
WO2010036822A1 (en) * 2008-09-24 2010-04-01 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
US9310310B2 (en) 2011-08-26 2016-04-12 3M Innovative Properties Company Flowable dry powder composition

Also Published As

Publication number Publication date
US20120296105A1 (en) 2012-11-22
US20220002338A1 (en) 2022-01-06
US20160175322A9 (en) 2016-06-23
KR20100132539A (ko) 2010-12-17
JP2015042686A (ja) 2015-03-05
AU2009231589A1 (en) 2009-10-08
HUE028337T2 (en) 2016-12-28
CA2728889A1 (en) 2009-10-08
US20170152281A1 (en) 2017-06-01
US20090291933A1 (en) 2009-11-26
US20180208623A1 (en) 2018-07-26
US20200190133A1 (en) 2020-06-18
US10995112B2 (en) 2021-05-04
US20160083415A1 (en) 2016-03-24
JP2011527986A (ja) 2011-11-10
CN102215845A (zh) 2011-10-12
US9877972B2 (en) 2018-01-30
US9555046B2 (en) 2017-01-31
ES2562069T3 (es) 2016-03-02
US9850271B2 (en) 2017-12-26
KR101545300B1 (ko) 2015-08-18
EP2273994A2 (en) 2011-01-19
PL2273994T3 (pl) 2016-05-31
WO2009124300A3 (en) 2011-06-23
WO2009124300A2 (en) 2009-10-08
US20160045516A1 (en) 2016-02-18
AU2009231589B2 (en) 2013-11-07
EP2273994B1 (en) 2015-12-02
US20120302537A1 (en) 2012-11-29
US8252947B2 (en) 2012-08-28
CA2728889C (en) 2016-06-14
EP2273994A4 (en) 2012-05-30
DK2273994T3 (en) 2016-02-01

Similar Documents

Publication Publication Date Title
ZA201104336B (en) Pharmaceutical compounds
EP2339918A4 (en) PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE
IL207378A0 (en) Pharmaceutical solid state forms
GB0816372D0 (en) Pharmaceutical compounds
GB0820819D0 (en) Pharmaceutical compounds
GB0801416D0 (en) Pharmaceutical compounds
IL216256A0 (en) A pharmaceutical composition
GB0816371D0 (en) Pharmaceutical compounds
ZA201104348B (en) Pharmaceutical preparation
PL2285413T3 (pl) Kompozycja farmaceutyczna
GB0810615D0 (en) Novel pharmaceutical
GB0812969D0 (en) Pharmaceutical compounds
PL2271618T3 (pl) Farmaceutyczne związki
GB0816370D0 (en) Pharmaceutical compounds
PT2273994E (pt) Formas de estado sólido de um produto farmacêutico
GB0815972D0 (en) Pharmaceutical preparation
GB0922589D0 (en) Pharmaceutical compounds
GB0810857D0 (en) Pharmaceutical compounds
ZA201008115B (en) A solid pharmaceutical formulation
IL245577A0 (en) Dose unit of efdanosone
GB0813347D0 (en) A set of parts
GB0810617D0 (en) Novel pharmaceutical
GB0908905D0 (en) Pharmaceutical compounds
GB0917775D0 (en) Novel pharmaceutical compounds
HU0800414D0 (en) Pharmaceutical combination